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SCIENTIFIC OPINION 
Scientific Opinion on the substantiation of health claims related to casein 
protein hydrolysates and growth or maintenance of muscle mass (ID 1498), 
increase in endurance performance (ID 660, 1497) and faster recovery from 
muscle fatigue after exercise (ID 660, 1497) pursuant to Article 13(1) of 
Regulation (EC) No 1924/2006
1
 
EFSA Panel on Dietetic Products, Nutrition and Allergies (NDA)
2,
 
3
 
European Food Safety Authority (EFSA), Parma, Italy 
SUMMARY 
Following a request from the European Commission, the Panel on Dietetic Products, Nutrition and 
Allergies was asked to provide a scientific opinion on a list of health claims pursuant to Article 13 of 
Regulation (EC) No 1924/2006. This opinion addresses the scientific substantiation of health claims 
in relation to casein protein hydrolysates and growth or maintenance of muscle mass, increase in 
endurance performance and faster recovery from muscle fatigue after exercise. The scientific 
substantiation is based on the information provided by the Member States in the consolidated list of 
Article 13 health claims and references that EFSA has received from Member States or directly from 
stakeholders. 
The food constituent that is the subject of the health claims is casein protein hydrolysates. The Panel 
considers that casein protein hydrolysates are sufficiently characterised in relation to the claimed 
effects. 
Growth or maintenance of muscle mass (ID 1498) 
The claimed effect is “absorption rate and muscle accretion”. The target population is assumed to be 
the general population. In the context of the proposed wordings and clarifications provided by 
Member States, the Panel assumes that the claimed effect refers to the growth or maintenance of 
                                                     
1  On request from the European Commission, Question No EFSA-Q-2008-1447, EFSA-Q-2008-2234, EFSA-Q-2008-2235, 
adopted on 25 March 2011. 
2  Panel members: Carlo Agostoni, Jean-Louis Bresson, Susan Fairweather-Tait, Albert Flynn, Ines Golly, Hannu Korhonen, 
Pagona Lagiou, Martinus Løvik, Rosangela Marchelli, Ambroise Martin, Bevan Moseley, Monika Neuhäuser-Berthold, 
Hildegard Przyrembel, Seppo Salminen, Yolanda Sanz, Sean (J.J.) Strain, Stephan Strobel, Inge Tetens, Daniel Tomé, 
Hendrik van Loveren and Hans Verhagen. Correspondence: nda@efsa.europa.eu 
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on Weight Management/Satiety/Glucose and Insulin Control/Physical Performance: Kees de Graaf, Joanne Harrold, Mette 
Hansen, Mette Kristensen, Anders Sjödin and Inge Tetens. 
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muscle mass. The Panel considers that growth or maintenance of muscle mass is a beneficial 
physiological effect.  
A claim on protein and growth or maintenance of muscle mass has been assessed by the Panel with a 
favourable outcome (EFSA Panel on Dietetic Products Nutrition and Allergies (NDA), 2010).  
No human studies which investigated the effects of casein protein hydrolysates on muscle mass or 
muscle strength were provided. 
On the basis of the data presented, the Panel concludes that a cause and effect relationship has not 
been established between the consumption of casein protein hydrolysates and growth or maintenance 
of muscle mass apart from the well established role of protein on the claimed effect. 
Increase in endurance performance (ID 660, 1497) 
The claimed effect is “physical performance”. The target population is assumed to be adults 
performing endurance exercise.  
In the context of the proposed wordings, the Panel assumes that the claimed effect refers to an 
increase in endurance performance. The Panel considers that an increase in endurance performance is 
a beneficial physiological effect. 
No studies have been provided from which conclusions could be drawn for the scientific 
substantiation of the claim. 
On the basis on the data presented, the Panel concludes that a cause and effect relationship has not 
been established between the consumption of casein protein hydrolysates and increase in endurance 
performance. 
Faster recovery from muscle fatigue after exercise (ID 660, 1497) 
The claimed effect is “physical performance”. The target population is assumed to be adults 
performing strenuous exercise. In the context of the proposed wordings, the Panel assumes that the 
claimed effect refers to muscle fatigue recovery. The Panel considers that faster recovery from muscle 
fatigue after exercise is a beneficial physiological effect. 
No studies have been provided from which conclusions could be drawn for the scientific 
substantiation of the claim. 
On the basis of the data presented, the Panel concludes that a cause and effect relationship has not 
been established between the consumption of casein protein hydrolysates and faster recovery from 
muscle fatigue after exercise. 
KEY WORDS 
Casein protein hydrolysates, muscle mass, endurance performance, muscle fatigue, health claims. 
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INFORMATION AS PROVIDED IN THE CONSOLIDATED LIST 
The consolidated list of health claims pursuant to Article 13 of Regulation (EC) No 1924/2006
4
 
submitted by Member States contains main entry claims with corresponding conditions of use and 
literature for similar health claims. EFSA has screened all health claims contained in the original 
consolidated list of Article 13 health claims which was received by EFSA in 2008 using six criteria 
established by the NDA Panel to identify claims for which EFSA considered sufficient information 
had been provided for evaluation and those for which more information or clarification was needed 
before evaluation could be carried out
5
. The clarifications which were received by EFSA through the 
screening process have been included in the consolidated list. This additional information will serve 
as clarification to the originally provided information. The information provided in the consolidated 
list for the health claims which are the subject of this opinion is tabulated in Appendix C.  
ASSESSMENT 
1. Characterisation of the food/constituent 
The food constituent that is the subject of the health claims is casein protein hydrolysates. 
Casein is a phosphoprotein present in mammal’s milk, and accounts for about 80 % of proteins in cow 
milk. Different casein hydrolysates (typically containing di- and tripeptides) are available on the 
market. Differences in composition between different casein protein hydrolysates may exist 
depending on the manufacturing processes applied. These products generally have a high content of 
essential amino acids. 
A claim on protein and growth or maintenance of muscle mass has been assessed by the Panel with a 
favourable outcome (EFSA Panel on Dietetic Products Nutrition and Allergies (NDA), 2010). In the 
current opinion, the Panel addressed whether the consumption of casein protein hydrolysates has any 
effect on growth or maintenance of muscle mass apart from the well established role of protein on the 
claimed effect. 
The Panel considers that the food constituent, casein protein hydrolysates, which is the subject of the 
health claims, is sufficiently characterised in relation to the claimed effects. 
2. Relevance of the claimed effect to human health 
2.1. Growth or maintenance of muscle mass (ID 1498) 
The claimed effect is “absorption rate and muscle accretion”. The Panel assumes that the target 
population is the general population.  
In the context of the proposed wordings and clarifications provided by Member States, the Panel 
assumes that the claimed effect refers to the growth or maintenance of muscle mass. Failure to 
increase muscle mass during growth and development, and the loss of muscle mass at any age, will 
reduce muscle strength and power. 
The Panel considers that growth or maintenance of muscle mass is a beneficial physiological effect. 
                                                     
4 Regulation (EC) No 1924/2006 of the European Parliament and of the Council of 20 December 2006 on nutrition and 
health claims made on foods. OJ L 404, 30.12.2006, p. 9–25.  
5 EFSA Panel on Dietetic Products, Nutrition and Allergies (NDA), 2011. General guidance for stakeholders on the 
evaluation of Article 13.1, 13.5 and 14 health claims. EFSA Journal, 9(4):2135, 24 pp. 
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2.2. Increase in endurance performance (ID 660, 1497) 
The claimed effect is “physical performance”. The Panel assumes that the target population is adults 
performing endurance exercise. 
In the context of the proposed wordings, the Panel assumes that the claimed effect refers to an 
increase in endurance performance.   
Endurance performance relates to the ability to complete certain tasks with higher intensity, faster, or 
with a higher power output when performing long-term exercise.  
The Panel considers that an increase in endurance performance is a beneficial physiological effect. 
2.3. Faster recovery from muscle fatigue after exercise (ID 660, 1497) 
The claimed effect is “physical performance”. The Panel assumes that the target population is adults 
performing strenuous exercise. 
In the context of the proposed wordings, the Panel assumes that the claimed effect refers to muscle 
fatigue recovery.  
Fatigue can be defined as the loss of peak force or power output. Therefore, muscle fatigue recovery 
can be defined as the regaining of maximal muscle strength or muscle power after strenuous exercise 
that has induced muscle fatigue. Regaining muscle strength/power may be beneficial during everyday 
life activities, and is beneficial for athletic performance in disciplines where loss of muscle strength 
and power reduces performance.  
The Panel considers that faster recovery from muscle fatigue after exercise is a beneficial 
physiological effect. 
3. Scientific substantiation of the claimed effect 
3.1. Growth or maintenance of muscle mass (ID 1498) 
A claim on protein and growth or maintenance of muscle mass has been assessed by the Panel with a 
favourable outcome (EFSA Panel on Dietetic Products Nutrition and Allergies (NDA), 2010). The 
references provided in relation to the current claim reported on health outcomes other than muscle 
growth or maintenance (e.g. acute protein synthesis and protein turnover, plasma amino acid profiles, 
and appetite). The Panel considers that no conclusions can be drawn from these references for the 
scientific substantiation of the claim. 
No human studies which investigated the effects of casein protein hydrolysates on muscle mass or 
muscle strength were provided. 
The Panel concludes that a cause and effect relationship has not been established between the 
consumption of casein protein hydrolysates and growth or maintenance of muscle mass apart from the 
well established role of protein on the claimed effect. 
3.2. Increase in endurance performance (ID 660, 1497) 
The references provided in relation to this claim either assessed the effects of foods or food 
constituents other than casein protein hydrolysates (e.g. other protein sources such as whey protein, 
skimmed milk, soy protein, single amino acids and branched-chain amino acids), or assessed the 
Casein protein hydrolysates related health claims 
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effects of casein protein hydrolysates in combination with other food constituents (e.g. carbohydrates) 
which could have contributed to the claimed effect. The Panel considers that no conclusions can be 
drawn from these references for the scientific substantiation of the claim. 
The Panel concludes that a cause and effect relationship has not been established between the 
consumption of casein protein hydrolysates and increase in endurance performance. 
3.3. Faster recovery from muscle fatigue after exercise (ID 660, 1497) 
The references provided in relation to this claim either assessed the effects of foods or food 
constituents other than casein protein hydrolysates (e.g. other protein sources such as whey protein, 
skimmed milk, soy protein, single amino acids and branched-chain amino acids), or assessed the 
effects of casein protein hydrolysates in combination with other food constituents (e.g. carbohydrates) 
which could have contributed to the claimed effect. The Panel considers that no conclusions can be 
drawn from these references for the scientific substantiation of the claim. 
The Panel concludes that a cause and effect relationship has not been established between the 
consumption of casein protein hydrolysates and faster recovery from muscle fatigue after exercise. 
CONCLUSIONS  
On the basis of the data presented, the Panel concludes that: 
 The food constituent, casein protein hydrolysates, which is the subject of the health claims, is 
sufficiently characterised in relation to the claimed effects. 
Growth or maintenance of muscle mass (ID 1496) 
 The claimed effect is “absorption rate and muscle accretion”. The target population is 
assumed to be the general population. Growth or maintenance of muscle mass is a beneficial 
physiological effect. 
 A cause and effect relationship has not been established between the consumption of casein 
protein hydrolysates and growth or maintenance of muscle mass apart from the well 
established role of protein on the claimed effect. 
Increase in endurance performance (ID 660, 1497) 
 The claimed effect is “physical performance”. The target population is assumed to be adults 
performing endurance exercise. In the context of the proposed wordings, it is assumed that the 
claimed effect refers to an increase in endurance performance. An increase in endurance 
performance is a beneficial physiological effect. 
 A cause and effect relationship has not been established between the consumption of casein 
protein hydrolysates and increase in endurance performance. 
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Faster recovery from muscle fatigue after exercise (ID 660, 1497) 
 The claimed effect is “physical performance”. The target population is adults performing 
strenuous exercise. Faster recovery from muscle fatigue after exercise is a beneficial 
physiological effect. 
 A cause and effect relationship has not been established between the consumption of casein 
protein hydrolysates and faster recovery from muscle fatigue after exercise. 
DOCUMENTATION PROVIDED TO EFSA 
Health claims pursuant to Article 13 of Regulation (EC) No 1924/2006 (No: EFSA-Q-2008-1447, 
EFSA-Q-2008-2234, EFSA-Q-2008-2235). The scientific substantiation is based on the information 
provided by the Member States in the consolidated list of Article 13 health claims and references that 
EFSA has received from Member States or directly from stakeholders. 
The full list of supporting references as provided to EFSA is available on: 
http://www.efsa.europa.eu/panels/nda/claims/article13.htm. 
REFERENCES  
EFSA Panel on Dietetic Products Nutrition and Allergies (NDA), 2010. Scientific Opinion on the 
substantiation of health claims related to protein and increase in satiety leading to a reduction in 
energy intake (ID 414, 616, 730), contribution to the maintenance or achievement of a normal 
body weight (ID 414, 616, 730), maintenance of normal bone (ID 416) and growth or maintenance 
of muscle mass (ID 415, 417, 593, 594, 595, 715) pursuant to Article 13(1) of Regulation (EC) No 
1924/2006. EFSA Journal, 8(10):1811, 24 pp. 
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APPENDICES 
APPENDIX A 
BACKGROUND AND TERMS OF REFERENCE AS PROVIDED BY THE EUROPEAN COMMISSION 
The Regulation 1924/2006 on nutrition and health claims made on foods
6
 (hereinafter "the 
Regulation") entered into force on 19
th
 January 2007. 
Article 13 of the Regulation foresees that the Commission shall adopt a Community list of permitted 
health claims other than those referring to the reduction of disease risk and to children's development 
and health. This Community list shall be adopted through the Regulatory Committee procedure and 
following consultation of the European Food Safety Authority (EFSA). 
Health claims are defined as "any claim that states, suggests or implies that a relationship exists 
between a food category, a food or one of its constituents and health". 
In accordance with Article 13 (1) health claims other than those referring to the reduction of disease 
risk and to children's development and health are health claims describing or referring to:  
a) the role of a nutrient or other substance in growth, development and the functions of the 
body; or 
b) psychological and behavioural functions; or 
c) without prejudice to Directive 96/8/EC, slimming or weight-control or a reduction in the 
sense of hunger or an increase in the sense of satiety or to the reduction of the available 
energy from the diet. 
To be included in the Community list of permitted health claims, the claims shall be: 
(i) based on generally accepted scientific evidence; and 
(ii) well understood by the average consumer. 
Member States provided the Commission with lists of claims as referred to in Article 13 (1) by 31 
January 2008 accompanied by the conditions applying to them and by references to the relevant 
scientific justification. These lists have been consolidated into the list which forms the basis for the 
EFSA consultation in accordance with Article 13 (3). 
ISSUES THAT NEED TO BE CONSIDERED 
IMPORTANCE AND PERTINENCE OF THE FOOD
7
  
Foods are commonly involved in many different functions
8
 of the body, and for one single food many 
health claims may therefore be scientifically true. Therefore, the relative importance of food e.g. 
nutrients in relation to other nutrients for the expressed beneficial effect should be considered: for 
functions affected by a large number of dietary factors it should be considered whether a reference to 
a single food is scientifically pertinent. 
                                                     
6 OJ L12, 18/01/2007 
7 The term 'food' when used in this Terms of Reference refers to a food constituent, the food or the food category.  
8 The term 'function' when used in this Terms of Reference refers to health claims in Article 13(1)(a), (b) and (c).  
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It should also be considered if the information on the characteristics of the food contains aspects 
pertinent to the beneficial effect. 
SUBSTANTIATION OF CLAIMS BY GENERALLY ACCEPTABLE SCIENTIFIC EVIDENCE 
Scientific substantiation is the main aspect to be taken into account to authorise health claims. Claims 
should be scientifically substantiated by taking into account the totality of the available scientific 
data, and by weighing the evidence, and shall demonstrate the extent to which: 
(a) the claimed effect of the food is beneficial for human health, 
(b) a cause and effect relationship is established between consumption of the food and the 
claimed effect in humans (such as: the strength, consistency, specificity, dose-
response, and biological plausibility of the relationship), 
(c) the quantity of the food and pattern of consumption required to obtain the claimed 
effect could reasonably be achieved as part of a balanced diet, 
(d) the specific study group(s) in which the evidence was obtained is representative of the 
target population for which the claim is intended. 
EFSA has mentioned in its scientific and technical guidance for the preparation and presentation of 
the application for authorisation of health claims consistent criteria for the potential sources of 
scientific data. Such sources may not be available for all health claims. Nevertheless it will be 
relevant and important that EFSA comments on the availability and quality of such data in order to 
allow the regulator to judge and make a risk management decision about the acceptability of health 
claims included in the submitted list. 
The scientific evidence about the role of a food on a nutritional or physiological function is not 
enough to justify the claim. The beneficial effect of the dietary intake has also to be demonstrated. 
Moreover, the beneficial effect should be significant i.e. satisfactorily demonstrate to beneficially 
affect identified functions in the body in a way which is relevant to health. Although an appreciation 
of the beneficial effect in relation to the nutritional status of the European population may be of 
interest, the presence or absence of the actual need for a nutrient or other substance with nutritional or 
physiological effect for that population should not, however, condition such considerations. 
Different types of effects can be claimed. Claims referring to the maintenance of a function may be 
distinct from claims referring to the improvement of a function. EFSA may wish to comment whether 
such different claims comply with the criteria laid down in the Regulation. 
WORDING OF HEALTH CLAIMS 
Scientific substantiation of health claims is the main aspect on which EFSA's opinion is requested. 
However, the wording of health claims should also be commented by EFSA in its opinion. 
There is potentially a plethora of expressions that may be used to convey the relationship between the 
food and the function. This may be due to commercial practices, consumer perception and linguistic 
or cultural differences across the EU. Nevertheless, the wording used to make health claims should be 
truthful, clear, reliable and useful to the consumer in choosing a healthy diet. 
In addition to fulfilling the general principles and conditions of the Regulation laid down in Article 3 
and 5, Article 13(1)(a) stipulates that health claims shall describe or refer to "the role of a nutrient or 
other substance in growth, development and the functions of the body". Therefore, the requirement to 
Casein protein hydrolysates related health claims 
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describe or refer to the 'role' of a nutrient or substance in growth, development and the functions of 
the body should be carefully considered. 
The specificity of the wording is very important. Health claims such as "Substance X supports the 
function of the joints" may not sufficiently do so, whereas a claim such as "Substance X helps 
maintain the flexibility of the joints" would. In the first example of a claim it is unclear which of the 
various functions of the joints is described or referred to contrary to the latter example which 
specifies this by using the word "flexibility". 
The clarity of the wording is very important. The guiding principle should be that the description or 
reference to the role of the nutrient or other substance shall be clear and unambiguous and therefore 
be specified to the extent possible i.e. descriptive words/ terms which can have multiple meanings 
should be avoided. To this end, wordings like "strengthens your natural defences" or "contain 
antioxidants" should be considered as well as "may" or "might" as opposed to words like 
"contributes", "aids" or "helps".  
In addition, for functions affected by a large number of dietary factors it should be considered 
whether wordings such as "indispensable", "necessary", "essential" and "important" reflects the 
strength of the scientific evidence. 
Similar alternative wordings as mentioned above are used for claims relating to different relationships 
between the various foods and health. It is not the intention of the regulator to adopt a detailed and 
rigid list of claims where all possible wordings for the different claims are approved. Therefore, it is 
not required that EFSA comments on each individual wording for each claim unless the wording is 
strictly pertinent to a specific claim. It would be appreciated though that EFSA may consider and 
comment generally on such elements relating to wording to ensure the compliance with the criteria 
laid down in the Regulation. 
In doing so the explanation provided for in recital 16 of the Regulation on the notion of the average 
consumer should be recalled. In addition, such assessment should take into account the particular 
perspective and/or knowledge in the target group of the claim, if such is indicated or implied. 
TERMS OF REFERENCE 
HEALTH CLAIMS OTHER THAN THOSE REFERRING TO THE REDUCTION OF DISEASE RISK AND TO 
CHILDREN'S DEVELOPMENT AND HEALTH 
EFSA should in particular consider, and provide advice on the following aspects: 
 Whether adequate information is provided on the characteristics of the food pertinent to the 
beneficial effect. 
 Whether the beneficial effect of the food on the function is substantiated by generally 
accepted scientific evidence by taking into account the totality of the available scientific data, 
and by weighing the evidence. In this context EFSA is invited to comment on the nature and 
quality of the totality of the evidence provided according to consistent criteria. 
 The specific importance of the food for the claimed effect. For functions affected by a large 
number of dietary factors whether a reference to a single food is scientifically pertinent. 
In addition, EFSA should consider the claimed effect on the function, and provide advice on the 
extent to which: 
 the claimed effect of the food in the identified function is beneficial. 
 a cause and effect relationship has been established between consumption of the food and the 
claimed effect in humans and whether the magnitude of the effect is related to the quantity 
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12 EFSA Journal 2011;9(6):2213 
consumed. 
 where appropriate, the effect on the function is significant in relation to the quantity of the 
food proposed to be consumed and if this quantity could reasonably be consumed as part of a 
balanced diet.  
 the specific study group(s) in which the evidence was obtained is representative of the target 
population for which the claim is intended. 
 the wordings used to express the claimed effect reflect the scientific evidence and complies 
with the criteria laid down in the Regulation.  
When considering these elements EFSA should also provide advice, when appropriate: 
 on the appropriate application of Article 10 (2) (c) and (d) in the Regulation, which provides 
for additional labelling requirements addressed to persons who should avoid using the food; 
and/or warnings for products that are likely to present a health risk if consumed to excess. 
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APPENDIX B 
EFSA DISCLAIMER 
The present opinion does not constitute, and cannot be construed as, an authorisation to the marketing 
of the food/food constituent, a positive assessment of its safety, nor a decision on whether the 
food/food constituent is, or is not, classified as foodstuffs. It should be noted that such an assessment 
is not foreseen in the framework of Regulation (EC) No 1924/2006. 
It should also be highlighted that the scope, the proposed wordings of the claims and the conditions of 
use as proposed in the Consolidated List may be subject to changes, pending the outcome of the 
authorisation procedure foreseen in Article 13(3) of Regulation (EC) No 1924/2006. 
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APPENDIX C 
Table 1. Main entry health claims related to casein protein hydrolysates, including conditions of use 
from similar claims, as proposed in the Consolidated List. 
ID Food or Food constituent Health Relationship Proposed wording 
660 Casein protein hydrolysate Physical performance Can accelerate recovery from 
exercise can help to recover faster 
can shorten the time to recover 
completely 
can help to enhance endurance 
performance 
can help to perform longer 
can support endurance performance 
can increase;endurance 
performance 
can increase time to fatigue;during 
exercise 
can help to enhance 
physical;performance 
can help to perform better 
can support;physical performance 
can help to increase physical 
performance 
can help to reduce exercise induced 
muscle damage 
can help to reduce exercise induced 
muscle pain 
can protect muscle during exercise 
Conditions of use 
- 10-30 g protein consumption; just before, during or directly after exercise per hour 
ID Food or Food constituent Health Relationship Proposed wording 
1497 Casein protein hydrolysate Physical performance Accelerates recovery from exercise 
helps to recover faster 
shortens the time to recover 
completely 
helps to enhance endurance 
performance 
helps to perform longer 
supports endurance performance 
increases endurance performance 
increases time to fatigue during 
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exercise 
helps to enhance physical 
performance 
helps to perform better 
supports physical performance 
helps to increase physical 
performance 
protects muscle during exercise 
Conditions of use 
- 10-30 g protein consumption just before, during or directly after exercise per hour.  
ID Food or Food constituent Health Relationship Proposed wording 
1498 Casein Absorption rate and 
muscle accretion 
Clarification provided 
Increases protein 
synthesis into muscle 
mass 
Slower absorbing protein source to 
deliver essential amino acids to 
muscles for exercise recovery  
Post-exercise consumption supports 
muscle anabolism 
Conditions of use 
- The product must contain at least 10 grams high quality protein per serving 
- Claim to be used for foods for active individuals 
 
 
